# Eventum Orthopaedics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eventum-orthopaedics

- Industry: Medical Devices & Equipment
- Headquarters: Leeds, UK
- Website: www.eventumortho.com
- Total disclosed funding: $3M
- Latest round: Series A (Dec 20, 2022)
- Investors on record: 1

## About

Eventum Orthopaedics Ltd., based in the UK, specializes in developing advanced medical devices aimed at improving outcomes in orthopedic surgeries, particularly Total Knee Arthroplasty (TKA).Established in 2020 and headquartered in Leeds, UK, Eventum Orthopaedics focuses on creating innovative solutions for orthopedic surgeons. The founders, John Naybour, Paul Atherton, and Paul Naybour, have a background in medical device development. The company has successfully completed three funding rounds, with the most recent round in March 2025 raising GBP 3.8 million from Mercia Asset Management. This funding contributes to the total amount raised of GBP 3.8 million.Eventum Orthopaedics specializes in developing innovative medical devices designed to enhance patient outcomes in orthopedic surgeries, particularly Total Knee Arthroplasty (TKA). Their flagship product, Quadsense, provides real-time intraoperative data that enables surgeons to make informed decisions regarding patellar loading and knee joint function during surgery. Released in September 2024, Quadsense has received 510K clearance from the FDA, highlighting its regulatory approval and market readiness. The company is also developing Datasense, a comprehensive data analysis tool that integrates preoperative, intraoperative, and postoperative patient data to further assist surgeons in optimizing clinical decision-making. Eventum serves a global market, targeting healthcare providers and orthopedic surgeons primarily in North America, Europe, and Asia, focusing on addressing the significant issue of patient dissatisfaction following knee replacement surgeries.Eventum Orthopaedics generates revenue through direct sales of its medical devices, particularly its Quadsense product, to healthcare providers and surgical centers. Transactions typically occur through a business-to-business (B2B) model, where hospitals and surgical clinics purchase the device outright or potentially engage in partnerships for ongoing support and updates. The pricing structure is based on the sale of individual units of Quadsense, as well as potential licensing agreements for the use of the Datasense tool. The company has secured GBP 1.4 million in funding, which indicates investor confidence in its product offerings and business model. By providing innovative solutions that directly address the challenges faced by orthopedic surgeons, Eventum aims to create a sustainable revenue stream while enhancing patient care.In March 2025, Eventum Orthopaedics Ltd. raised GBP 3.8 million in venture funding led by returning investor Mercia Asset Management. The company will use this funding to build stock of its Quadsense device for its launch in the UK, US, and New Zealand, and to develop two additional medical devices. This strategic funding will enable Eventum to expand its market presence and enhance its product lineup.

## Funding rounds

- Series A, Dec 20, 2022, $3M — Mercia Asset Management

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Series A